EIGR Eiger BioPharmaceuticals Inc.

10.81
-0.74  -6%
Previous Close 11.55
Open 11.65
Price To book 4.38
Market Cap 90437554
Shares 8,367,030
Volume 128,995
Short Ratio 1.47
Av. Daily Volume 85,811

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data presented at ADA meeting June 11, 2017. Completion of PK study 3Q 2017. Phase 2 - 28-day study initiation due 4Q 2017 data 1H 2018.
Subcutaneous exendin - MAD study
Post-Bariatric Hypoglycemia (PBH)
Noted July 24, 2017 that enrollment has been completed. Interim data due at AASLD, October 20 -24, 2017.
Pegylated Interferon Lambda (LIMT HDV)
Hepatitis delta virus (HDV)
Phase 2 end of trial data released April 21, 2017. Meeting with FDA scheduled for 4Q 2017.
Lonafarnib - LOWR HDV
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 4
Chronic hepatitis delta virus (HDV)
Phase 2 presentation at AASLD November 14, 2016.
Lonafarnib - LOWR HDV – 3
Chronic hepatitis delta virus (HDV)
Phase 2 initiated July 2016. Enrollment completion announced May 15, 2017 with data due 1Q 2018 at JPM Conference - January 8-11, 2018.
Ubenimex - LIBERTY
Pulmonary arterial hypertension (PAH)
Phase 2 dosing commenced July 2016. Enrollment to be completed 4Q 2017. Data due 2Q 2018.
Ubenimex - ULTRA
Secondary lymphedema
Phase 2b negative data released April 2015. Formerly CLDN pre-merger
MYDICAR - CUPID 2 Trial
Ischemic or dilated cardiomyopathy

Latest News

  1. Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors
  2. Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
  3. Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences
  4. Eiger BioPharma reports 2Q loss
  5. Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
  6. Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th
  7. Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
  8. Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
  9. Eiger BioPharmaceuticals (EIGR) Rises: Stock Climbs 24%
  10. Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
  11. Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors
  12. Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego
  13. Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients
  14. Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th
  15. Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema
  16. Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension
  17. Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results
  18. Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago
  19. Eiger BioPharmaceuticals to Host Key Opinion Leader Event Addressing Need for Novel Mechanisms in the Treatment of Pulmonary Arterial Hypertension (PAH) on May 10th in New York City

SEC Filings

  1. 8-K - Current report 171089952
  2. 8-K - Current report 171066846
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 171044641
  4. S-8 - Securities to be offered to employees in employee benefit plans 171026137
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171025524
  6. 8-K - Current report 17911284
  7. 8-K - Current report 17838715
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 17837317
  9. DEF 14A - Other definitive proxy statements 17796446
  10. 8-K - Current report 17708193